Search Results - "Kelley, Ryan M."

Conserved patterns of protein interaction in multiple species by Sharan, R, Suthram, S, Kelley, R.M, Kuhn, T, McCuine, S, Uetz, P, Sittler, T, Karp, R.M, Ideker, T

“…To elucidate cellular machinery on a global scale, we performed a multiple comparison of the recently available protein-protein interaction networks of…”
Get full text

Corticostriatal Field Potentials Are Modulated at Delta and Theta Frequencies during Interval-Timing Task in Rodents by Emmons, Eric B, Ruggiero, Rafael N, Kelley, Ryan M, Parker, Krystal L, Narayanan, Nandakumar S

“…Organizing movements in time is a critical and highly conserved feature of mammalian behavior. Temporal control of action requires corticostriatal networks. We…”
Get full text

Human subthalamic nucleus neurons differentially encode speech and limb movement by Johari, Karim, Kelley, Ryan M, Tjaden, Kris, Patterson, Charity G, Rohl, Andrea H, Berger, Joel I, Corcos, Daniel M, Greenlee, Jeremy D W

“…Deep brain stimulation (DBS) of the subthalamic nucleus (STN), which consistently improves limb motor functions, shows mixed effects on speech functions in…”
Get full text

Effect of deep brain stimulation on vocal motor control mechanisms in Parkinson's disease by Behroozmand, Roozbeh, Johari, Karim, Kelley, Ryan M., Kapnoula, Efthymia C., Narayanan, Nandakumar S., Greenlee, Jeremy D.W.

“…Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective treatment for limb motor symptoms in Parkinson's disease (PD); however, its…”
Get full text

Discovery Tactics To Mitigate Toxicity Risks Due to Reactive Metabolite Formation with 2-(2-Hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one Derivatives, Potent Calcium-Sensing Receptor Antagonists and Clinical Candidate(s) for the Treatment of Osteoporosis by Kalgutkar, Amit S, Griffith, David A, Ryder, Tim, Sun, Hao, Miao, Zhuang, Bauman, Jonathan N, Didiuk, Mary T, Frederick, Kosea S, Zhao, Sabrina X, Prakash, Chandra, Soglia, John R, Bagley, Scott W, Bechle, Bruce M, Kelley, Ryan M, Dirico, Kenneth, Zawistoski, Michael, Li, Jianke, Oliver, Robert, Guzman-Perez, Angel, Liu, Kevin K. C, Walker, Daniel P, Benbow, John W, Morris, Joel

“…The synthesis and structure−activity relationship studies on 5-trifluoromethylpyrido[4,3-d]pyrimidin-4(3H)-ones as antagonists of the human calcium receptor…”
Get full text

Short-acting 5-(trifluoromethyl)pyrido[4,3- d]pyrimidin-4(3 H)-one derivatives as orally-active calcium-sensing receptor antagonists by Didiuk, Mary T., Griffith, David A., Benbow, John W., Liu, Kevin K.C., Walker, Daniel P., Christopher Bi, F., Morris, Joel, Guzman-Perez, Angel, Gao, Hua, Bechle, Bruce M., Kelley, Ryan M., Yang, Xiaojing, Dirico, Kenneth, Ahmed, Syed, Hungerford, William, DiBrinno, Joseph, Zawistoski, Michael P., Bagley, Scott W., Li, Jianke, Zeng, Yuan, Santucci, Stephanie, Oliver, Robert, Corbett, Matthew, Olson, Thanh, Chen, Chiliu, Li, Mei, Paralkar, Vishwas M., Riccardi, Keith A., Healy, David R., Kalgutkar, Amit S., Maurer, Tristan S., Nguyen, Hang T., Frederick, Kosea S.

“…Structure–activity relationship studies, focused on the optimization of pharmacology and pharmacokinetics, are described for a series of short-acting…”
Get full text

Metabolism, Pharmacokinetics, and Excretion of the 5-Hydroxytryptamine 1B Receptor Antagonist Elzasonan in Humans by Kamel, Amin, Obach, R. Scott, Colizza, Kevin, Wang, Weiwei, O'Connell, Thomas N., Coelho, Richard V., Kelley, Ryan M., Schildknegt, Klaas

Get full text

5-Hydroxytryptamine1B Receptor Antagonist Elzasonan in Humans by KAMEL, Amin, OBACH, R. Scott, COLIZZA, Kevin, WEIWEI WANG, O'CONNELL, Thomas N, COELHO, Richard V, KELLEY, Ryan M, SCHILDKNEGT, Klaas

Get full text

Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humans by Kamel, Amin, Obach, R Scott, Colizza, Kevin, Wang, Weiwei, O'Connell, Thomas N, Coelho, Jr, Richard V, Kelley, Ryan M, Schildknegt, Klaas

“…The metabolism, pharmacokinetics, and excretion of a potent and selective 5-hydroxytryptamine(1B) receptor antagonist elzasonan have been studied in six…”
Get full text